Analysts Are Bullish on Top Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Teva Pharmaceutical (TEVA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actuate Therapeutics, Inc. (ACTU – Research Report) and Teva Pharmaceutical (TEVA – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actuate Therapeutics, Inc. (ACTU)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Actuate Therapeutics, Inc., with a price target of $20.00. The company’s shares closed last Wednesday at $5.26.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of
Actuate Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.
See Insiders’ Hot Stocks on TipRanks >>
Teva Pharmaceutical (TEVA)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical, with a price target of $40.00. The company’s shares closed last Wednesday at $32.64.
According to TipRanks.com, Amsellem is a 4-star analyst with an average return of
Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $36.86, representing a 15.4% upside. In a report issued on January 11, J.P. Morgan also maintained a Buy rating on the stock.
